Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - oxymetazoline hydrochloride, quantity: 0.5 mg/ml - spray, nasal - excipient ingredients: benzyl alcohol; purified water; povidone; disodium edetate; macrogol 1450; dibasic sodium phosphate; benzalkonium chloride; monobasic sodium phosphate monohydrate; glycerol; dispersible cellulose; flavour - symptomatic relief of nasal and nasopharyngeal congestion associated with the common cold and flu, hayfever and sinusitis, and to facilitate visual intranasal examination. by decreasing congestion around the eustachian tube ostia, it may be useful in the adjunctive treatment of congestion associated with middle ear conditions.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - oxymetazoline hydrochloride, quantity: 0.5 mg/ml - spray, nasal - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); monobasic sodium phosphate dihydrate; sodium chloride; benzalkonium chloride; purified water - temporary relief of nasal and sinus congestion due to colds, influenza, sinusitis and allergies.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - oxymetazoline hydrochloride, quantity: 0.5 mg/ml - spray, nasal - excipient ingredients: benzalkonium chloride; sodium chloride; sorbitol solution (70 per cent) (non-crystallising); monobasic sodium phosphate dihydrate; purified water - temporary relief of nasal congestion due to colds, influenza, sinusitis and allergies

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - oxymetazoline hydrochloride, quantity: 0.5 mg/ml - spray, nasal - excipient ingredients: benzalkonium chloride; monobasic sodium phosphate dihydrate; sodium chloride; sorbitol solution (70 per cent) (crystallising); purified water - temporary relief of nasal and sinus congestion due to colds, influenza, sinusitis and allergies.

Estats Units - anglès - NLM (National Library of Medicine)

dynamic pharmaceuticals - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - oxymetazoline hydrochloride 0.2 mg in 0.4 ml - nasal decongestant temporarily relieves nasal congestion due to: - common cold - hay fever - upper respiratory allergies - helps clear nasal passages - shrinks swollen membranes - temporarily relieves sinus congestion and pressure

Estats Units - anglès - NLM (National Library of Medicine)

cadila healthcare limited - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - oxymetazoline hydrochloride 0.5 mg in 1 ml - nasal decongestant - temporarily relieves nasal congestion due to:                                    ■ a cold ■ hay fever ■ upper respiratory allergies - promotes nasal and sinus drainage - temporarily relieves sinus congestion and pressure - helps clear nasal passages; shrinks swollen membranes

Estats Units - anglès - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - oxymetazoline hydrochloride 0.5 mg in 1 ml - nasal decongestant - temporarily relieves nasal congestion due to:                                    ■ a cold ■ hay fever ■ upper respiratory allergies - promotes nasal and sinus drainage - temporarily relieves sinus congestion and pressure - helps clear nasal passages; shrinks swollen membranes

Estats Units - anglès - NLM (National Library of Medicine)

allergan, inc. - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - oxymetazoline hydrochloride 10 mg in 1 g - rhofade™ cream is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. none. risk summary there are no available data on rhofade use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. a literature article describing intranasal decongestant use in pregnant women identified a potential association between second-trimester exposure to oxymetazoline (with no decongestant exposure in the first trimester) and renal collecting system anomalies [ see data ] .  in animal reproduction studies, there were no adverse developmental effects observed after oral administration of oxymetazoline hydrochloride in pregnant rats and rabbits at systemic exposures up to 3 times and 73 times, respectively, the exposure associated with the maximum recommended human dose (mrhd) [see data] .  the estimated background risks of major birth defects and miscarriage for the indicated population are unknown.  all pregnancies have a background risk of bir

Estats Units - anglès - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - oxymetazoline hydrochloride cream is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. none. risk summary there are no available data on oxymetazoline hydrochloride use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. a literature article describing intranasal decongestant use in pregnant women identified a potential association between second-trimester exposure to oxymetazoline (with no decongestant exposure in the first trimester) and renal collecting system anomalies [see data] . in animal reproduction studies, there were no adverse developmental effects observed after oral administration of oxymetazoline hydrochloride in pregnant rats and rabbits at systemic exposures up to 3 times and 73 times, respectively, the exposure associated with the maximum recommended human dose (mrhd) [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. all pregnan

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - oxymetazoline hydrochloride -